Literature DB >> 20019269

Cancer research. Melanoma drug vindicates targeted approach.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20019269     DOI： 10.1126/science.326.5960.1619

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  13 in total

1.  Gene and drug matrix for personalized cancer therapy.

Authors:  Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

2.  Grand challenge commentary: Informative diagnostics for personalized medicine.

Authors:  Ryan C Bailey
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

3.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

4.  6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.

Authors:  Lucy Liu; Sangkil Nam; Yan Tian; Fan Yang; Jun Wu; Yan Wang; Anna Scuto; Panos Polychronopoulos; Prokopios Magiatis; Leandros Skaltsounis; Richard Jove
Journal:  Cancer Res       Date:  2011-05-24       Impact factor: 12.701

5.  Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Authors:  Sanxiong Xu; Zuozhang Yang; Jinyu Zhang; Yongxin Jiang; Yongbin Chen; Hongjun Li; Xuefeng Liu; Da Xu; Yanjin Chen; Yihao Yang; Ya Zhang; Dongxu Li; Junfeng Xia
Journal:  DNA Cell Biol       Date:  2015-01       Impact factor: 3.311

Review 6.  B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.

Authors:  Cynthia Shepherd; Igor Puzanov; Jeffrey A Sosman
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

7.  Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.

Authors:  Jing Hu; Eileen Friedman
Journal:  Genes Cancer       Date:  2010-08-01

8.  Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.

Authors:  Zhiwei Xie; Yixue Su; Gloria B Kim; Erhan Selvi; Chuying Ma; Virginia Aragon-Sanabria; Jer-Tsong Hsieh; Cheng Dong; Jian Yang
Journal:  Small       Date:  2016-12-27       Impact factor: 13.281

Review 9.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

10.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.